

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 April 2003 (03.04.2003)

PCT

(10) International Publication Number  
**WO 03/026744 A1**

(51) International Patent Classification<sup>7</sup>: **A61P 41/00**,  
27/06, 27/12, 35/00, A61K 31/427

(74) Agents: **COPELAND, Barry, L.** et al.; Intellectual  
Property Law and R & D Counsel, Alcon Research, LTD.  
(Q-148), 6201 South Freeway, Fort Worth, TX 76134-2099  
(US).

(21) International Application Number: PCT/US02/30315

(22) International Filing Date:  
25 September 2002 (25.09.2002)

(81) Designated States (*national*): AU, BR, CA, CN, JP, KP,  
KR, MX, PL, US, ZA.

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE, SK, TR).

(30) Priority Data:  
60/324,663 25 September 2001 (25.09.2001) US  
60/324,689 25 September 2001 (25.09.2001) US

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(71) Applicant (*for all designated States except US*): **ALCON,**  
INC. [CH/CH]; Bosch 69, CH-6331 Hünenberg (CH).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **KLIMKO, Peter, G.**  
[US/US]; 2115 Pembroke Drive, Fort Worth, TX 76110  
(US).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



**WO 03/026744 A1**

(54) Title: THE USE OF EPOTHILONES AND ANALOGS IN CONJUNCTION WITH OPHTHALMIC SURGERY

(57) Abstract: A method of use is disclosed for preventing or retarding posterior capsular opacification or scar formation following ophthalmic surgery by treatment of the surgical site with epothilones and analogs thereof.

## THE USE OF EPOTHILONES AND ANALOGS IN CONJUNCTION WITH OPHTHALMIC SURGERY

### FIELD OF THE INVENTION

5       The present invention is directed to the use of compositions containing epothilones and their analogs in conjunction with ophthalmic surgery. These compositions may be used to prevent or treat posterior capsular opacification following extracapsular extraction of a cataractous lens with or without artificial intraocular lens implantation. They may also be used to prevent or retard fistula closure resulted from  
10       glaucoma filtration surgery (GFS).

### BACKGROUND OF THE INVENTION

#### 1.       Cataracts

      Cataract extraction, a common surgical procedure, is performed on a patient when  
15       the natural crystallin lens of the eye becomes, for a variety of reasons, clouded or cataractous. Typically, the procedure involves i) making an incision in the anterior chamber of the eye in order to gain access to the lens capsular bag, ii) disintegration and removal of the defective lens, and iii) implantation of an artificial intraocular lens (IOL). A portion of the anterior membrane of the lens capsular bag is removed in order to allow  
20       implantation of the IOL. The capsular bag is normally cleaned by the ophthalmic surgeon in order to remove residual lens epithelial cells and other tissue debris. However it is difficult to remove all of the remnant tissue; consequently the residual lens epithelial cells frequently proliferate and cause eventual opacification of the IOL, leading to vision impairment in the patient. This result is termed posterior capsular opacification (PCO) or  
25       secondary cataract.

      Treatment of PCO after the fact typically involves the destruction of the undesirable tissue using a laser. However, this procedure can have significant sight-threatening complications, including without limitation damage to the IOL, injury or  
30       destruction of surrounding healthy tissue, and renewed PCO development. Therefore, it is generally thought to be preferable to prevent PCO at the time of the cataract surgery.

Administration of cytotoxic and cytostatic drugs to the affected site during surgery, such as 5-fluorouracil [Ruitz *et. al.*, Ophthalmic Res., volume 22, p. 201 (1990)], mitomycin C (ref), colchicine (ref), and taxol (Mannson *et. al.*, U.S. Patent No. 5,576,345) have been suggested in the art for PCO prevention. While these therapies can be helpful, serious side effects such as optic nerve and corneal epithelium toxicities sometimes occur. Thus, there remains a need for an efficacious therapy for the prevention and treatment of PCO incident to cataract extraction and IOL implantation.

## 2. Glaucoma

Glaucoma is a progressive disease which leads to optic nerve damage and, ultimately, total loss of vision. The causes of this disease have been the subject of extensive studies for many years, but are still not fully understood. The principal symptom of and/or risk factor for the disease is elevated intraocular pressure or ocular hypertension due to excess aqueous humor in the anterior chamber of the eye.

The causes of aqueous humor accumulation in the anterior chamber are not fully understood. It is known that elevated intraocular pressure ("IOP") can be at least partially controlled by administering drugs which either reduce the production of aqueous humor within the eye, such as beta-blockers and carbonic anhydrase inhibitors, or increase the outflow of aqueous humor from the eye, such as miotics and sympathomimetics.

Most types of drugs conventionally used to treat glaucoma have potentially serious side effects. Miotics such as pilocarpine can cause blurring of vision and other visual side effects, which may lead either to decreased patient compliance or to termination of therapy. Systemically administered carbonic anhydrase inhibitors (CAIs) can also cause serious side effects such as nausea, dyspepsia, fatigue, and metabolic acidosis, which can affect patient compliance and/or necessitate the termination of treatment. Another type of drug, beta-blockers, have increasingly become associated with serious pulmonary side effects attributable to their effects on beta-2 receptors in pulmonary tissue. Sympathomimetics, on the other hand, may cause tachycardia, arrhythmia and hypertension.

Recently introduced drugs to treat glaucoma, such as topical CAIs and prostaglandin analogues, have addressed some of these issues, but there are still patients whose pressures are not adequately controlled by drug therapy alone. In many of these cases there is a severe blockage of the normal passages for the outflow of aqueous humor. These patients may require surgery to restore the normal outflow of aqueous humor and thereby normalize their IOPs. The outflow of aqueous humor can be improved by various intraocular surgical procedures known to those skilled in the art, including without limitation trabeculectomy, posterior lip sclerectomy, and trephine and thermal sclerostomy. These surgical procedures are collectively known as glaucoma filtration surgery (GFS).

GFS generally involves the creation of a fistula to promote the drainage of aqueous humor. Typically, this includes the creation of an elevation of the conjunctiva at the surgical site. This elevation is commonly referred to as a filtering bleb. The filtering blebs which are most often associated with good IOP control are avascular and are either low profile and diffuse, or elevated with numerous cystic spaces. Studies have suggested that aqueous fluid in the filtering bleb usually filters through the conjunctiva and mixes with the tear film, or is adsorbed by vascular or perivascular conjunctival tissue.


Although GFS is generally successful at the start in lowering the patient's IOP to normal levels, over time scar tissue forms in the filtration bleb. This reduces the drainage capacity of the filtration system created by the surgery, which then causes the patient's IOP to return to abnormally high levels [see for example: Tahery, M.M.; *et. al. J. Ocul. Pharmacology*, volume 5, pp. 155-179 (1989); Tripathi, R.C. Drug Dev. Res., volume 22, pp. 1-23 (1991); "Glaucoma Filtering Procedures", in *Textbook of Glaucoma* (2<sup>nd</sup> edition), M. Bruce Shields editor, Wilkins & Wilkins: Baltimore, 1987, chapter 34, pp. 461-487]. In order to slow the scarring process, anti-inflammatory and antiproliferative agents can be applied to the surgical site. See, e.g. U.S. Patent No. 5,811,453, the contents of which are by this reference incorporated herein. However the use of these types of drugs has had only limited success. Many of these drugs cannot be

used at the concentrations which would be most effective at suppressing scar formation since they are toxic to other ophthalmic tissue. Furthermore the surgical failure rate (from re-closure of the surgically created bleb) is high in certain groups, such as patients with previous failed filtering surgery, prior cataract extraction, aphakia, or neovascular glaucoma. Other complications seen with these agents include corneal and conjunctival epithelial loss, corneal opacification, and wound leaks due to thin blebs. Thus there exists a need for an improved drug therapy to complement GFS in order to maintain the surgically achieved enhanced outflow by preventing fistula closure due to inappropriate scarring.

### 3. Epothilones

The epothilones are a family of macrolactones which potently inhibit the growth of cancer cells *in vitro* and the growth of tumors *in vivo* [Danishefsky *et. al.*, J. Org. Chem. vol. 64, p. 8434 (1999); Danishefsky *et. al.*, Proc. Natl. Acad. Sci. USA, issue 95, p. 9643 (1998); Nicolau *et. al.*, Angew. Chem. Intl. Ed. Engl., issue 37, p. 2014 (1998)]. They are among the most potent antitumor agents discovered to date and they maintain their efficacy against a wide range of multidrug-resistant cancers. It is believed that the ability of these compounds to inhibit inappropriate cell division is related to their ability to block the depolymerization of microtubules, and not due to direct cytotoxicity. For example, deoxyepothilone B (compound 1 below) has been shown to cause complete tumor regression in tumor-implanted mice without any noticeable toxic effects, whereas comparably effective doses of the standard anticancer agents adriamycin and paclitaxel

caused some animal deaths [Danishefsky *et. al.*, J. Org. Chem. vol. 64, p. 8434 (1999)].




1

## SUMMARY OF THE INVENTION

The present invention provides improved methods to prevent and/or retard the formation of secondary cataracts and/or ophthalmic scar tissue. The methods involve the administration of an ophthalmic composition containing one or more epothilones and/or analogs thereof to the surgical site at the time of or after surgery.

## DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention useful for the prevention or retardation of secondary cataracts and ophthalmic scarring, especially scarring associated with fistula closure after GFS are those of formula I:



wherein:

Y = O, NH, or a functionally modified amino group;

OR<sup>2</sup> and OR<sup>3</sup> = same or different = a free or functionally modified hydroxy group;

Z = O, NOH, or NNH<sub>2</sub>, where the OH and NH<sub>2</sub> may be free or functionally modified;

R<sup>1</sup> = H or optionally substituted alkyl;

--- = a single or double bond;

X is a direct bond (olefin stereochemistry in this case can be *E* or *Z*), O, CH<sub>2</sub>, OCH<sub>2</sub>, CH<sub>2</sub>O, S, NH, or a functionally modified amino group;

A is *E*- or *Z*-CR<sup>5</sup>=CHR<sup>6</sup> [the relative stereochemistry of this substituent can be α (down) or β (up)];

R<sup>5</sup> is H, alkyl, or halogen; and

R<sup>6</sup> is aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocycloalkyl.

Preferred compounds of formula I are those wherein:

Y is O or NH;

R<sup>2</sup> and R<sup>3</sup> are H;

Z is O;

R<sup>1</sup> is H or CH<sub>3</sub>;

--- = a single or double bond;


X is a direct bond, CH<sub>2</sub>, O, or NH;

A is *E*- or *Z*-CR<sup>5</sup>=CHR<sup>6</sup>, the substituent being in the β (up) position (the hydrogen at the A-bearing carbon being in the α position);

R<sup>5</sup> is H, C<sub>1-5</sub> alkyl, or Cl; and


R<sup>6</sup> is aryl or heteroaryl.

Among the especially preferred of the foregoing compounds are the seven below:




1

Source Reference:  
Danishefsky *et al.*,  
*Org. Lett.*, vol. 2, p.1633  
(2000)




2

Source Reference:  
Johnson *et al.*,  
*Org. Lett.*, vol. 2, p.1537  
(2000)




3

Source Reference:  
Danishefsky *et al.*,  
*Org. Lett.*, vol. 2, p.1637  
(2000)




4

Source Reference:  
Danishefsky *et al.*,  
*J. Org. Chem.* vol. 65,  
p.6525  
(2000)




5

Source Reference:  
Klar *et al.*,  
WO 00/49021 A2



6

Source Reference:  
Vite *et al.*,  
WO 99/54319 A2



7

Source Reference:  
Danishefsky *et al.*,  
*J. Am. Chem. Soc.*,  
vol. 124, p. 9825 (2002)

Included within the scope of the present invention are the individual enantiomers of the title compounds, as well as their racemic and non-racemic mixtures. Preferred are enantiomerically pure compositions (>98% enantiomeric excess of the desired enantiomer) with the absolute stereochemistry of the constituent molecules being as drawn for **I**. References for the synthesis of enantiomerically enriched samples of epothilones and analogs can be found, in addition to the epothilone-related literature cited above, in the following publications, all of which are incorporated in their entirety by reference: Johnson, J.; *et al.* *Org. Lett.*, 2:1537 (2000); Danishefsky, S.J. *et al.* *Org. Lett.*, volume 2, p. 1633 (2000); Danishefsky, S.J.; *et al.*, *Org. Lett.*, 2:1637 (2000); Danishefsky, S.J. *et al.*, *J. Am. Chem. Soc.*, 121:7050 (1999); Nicolaou, K.C. *et al.*, WO 99/67252 A2; Vite, G.D. *et al.*, WO 99/54330 A1; Danishefsky, S.J. *et al.*, WO 99/43653 A1; Vite, G.D. *et al.*, WO 99/54319 A1. Generally, the individual enantiomers can be



procured by a number of methods, including but not limited to: enantioselective synthesis from the appropriate enantiomerically pure or enriched starting material; synthesis from racemic/non-racemic or achiral starting materials using a chiral reagent, catalyst, solvent, etc. (see for example: *Asymmetric Synthesis*, J. D. Morrison and J. W. Scott, Eds.

5 Academic Press Publishers, (New York) 1985), volumes 1-5; *Principles of Asymmetric Synthesis*, R.E. Gawley and J. Aube, Eds.; Elsevier Publishers (Amsterdam 1996)); and isolation from racemic and non-racemic mixtures by a number of known methods, e.g. by purification of a sample by chiral HPLC (*A Practical Guide to Chiral Separations by HPLC*, G. Subramanian, Ed., VCH Publishers, (New York 1994); *Chiral Separations by HPLC*, A.M. Krstulovic, Ed., Ellis Horwood Ltd. Publishers (1989)), or by  
10 enantioselective hydrolysis of a carboxylic acid ester sample by an enzyme (Ohno, M.; Otsuka, M., Organic Reactions, 37:1 (1989)). Those skilled in the art will appreciate that racemic and non-racemic mixtures may be obtained by several means, including without limitation, nonenantioselective synthesis, partial resolution, or even mixing samples  
15 having different enantiomeric ratios. Departures may be made from such details within the scope of the accompanying claims without departing from the principles of the invention and without sacrificing its advantages. Also included within the scope of the present invention are the individual isomers substantially free of their respective enantiomers.

20 Wavy line attachments indicate that the configuration at that site may be either alpha ( $\alpha$ ) or beta ( $\beta$ ). Hatched lines indicate the  $\alpha$  configuration. A solid triangular line indicates the  $\beta$  configuration.

25 The term "free hydroxy group" means an OH. The term "functionally modified hydroxy group" means an OH which has been functionalized to form: an ether, in which an alkyl group is substituted for the hydrogen; an ester, in which an acyl group is substituted for the hydrogen; a carbamate, in which an aminocarbonyl group is substituted for the hydrogen; or a carbonate, in which an alkoxycarbonyl group is  
30 substituted for the hydrogen.

The term "free amino group" means an  $\text{NH}_2$ . The term "functionally modified amino group" means an  $\text{NH}_2$  which has been functionalized to form: an alkoxyamino or hydroxyamino group, in which an alkoxy or hydroxy group is substituted for one of the hydrogens; an alkylamino group, in which an alkyl group is substituted for one or both of the hydrogens; an amide, in which an acyl group is substituted for one of the hydrogens; a carbamate, in which an alkoxycarbonyl group is substituted for one of the hydrogens; a urea, in which an aminocarbonyl group is substituted for one of the hydrogens; or a sulfonamide, in which an alkylsulfonyl, a cycloalkylsulfonyl, a heterocycloalkylsulfonyl, a cycloalkenylsulfonyl, an arylsulfonyl, or a heteroaryl sulfonyl group is substituted for one of the hydrogens. Combinations of these substitution patterns, for example an  $\text{NH}_2$  in which one of the hydrogens is replaced by an alkyl group and the other hydrogen is replaced by an alkoxycarbonyl group, also fall under the definition of a functionally modified amino group and are included within the scope of the present invention.

The term "sulfonyl" represents an  $\text{SO}_2$ . The sulfonyl group is bonded from the sulfur atom to two other groups. For example, a dialkylsulfonyl group can be represented as  $\text{alkyl}^1\text{-SO}_2\text{-alkyl}^2$ , where  $\text{alkyl}^1$  and  $\text{alkyl}^2$  are the same or different alkyl groups, which are each bonded to the sulfur atom. An arylsulfonylamide can be represented by  $\text{aryl-SO}_2\text{-NWW}^1$ , where aryl is an aryl group and  $\text{NWW}^1$  is a free or functionally modified amino group, with the aryl and  $\text{NWW}^1$  groups being bonded to the sulfur atom.

The term "acyl" represents a group that is linked by a carbon atom that has a double bond to an oxygen atom and a single bond to another carbon atom.

The term "alkyl" includes straight or branched chain aliphatic hydrocarbon groups that are saturated and have 1 to 15 carbon atoms. The alkyl groups may be substituted with other groups, such as halogen, hydroxyl or alkoxy. Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and *t*-butyl.

The term "cycloalkyl" includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more rings, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkyl groups include  
5 cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "heterocycloalkyl" refers to cycloalkyl groups which contain at least one heteroatom such as O, S, or N in the ring. Heterocycloalkenyl rings may be isolated, with 5 to 8 ring atoms, or fused, with 8 to 10 atoms. The heterocycloalkyl ring(s)  
10 hydrogens or heteroatoms with open valency may be substituted with other groups, such as lower alkyl, acyl, or halogen. Preferred heterocycloalkyl groups include piperidine, piperazine, pyrrolidine, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydrothienyl.

The term "alkenyl" includes straight or branched chain hydrocarbon groups  
15 having 1 to 15 carbon atoms with at least one carbon-carbon double bond. The chain hydrogens may be substituted with other groups, such as halogen. Preferred straight or branched alkenyl groups include, allyl, 1-butenyl, 1-methyl-2-propenyl and 4-pentenyl.

The term "cycloalkenyl" includes straight or branched chain, saturated or  
20 unsaturated aliphatic hydrocarbon groups which connect to form one or more non-aromatic rings containing a carbon-carbon double bond, which can be fused or isolated. The rings may be substituted with other groups, such as halogen, hydroxyl, alkoxy, or lower alkyl. Preferred cycloalkenyl groups include cyclopentenyl and cyclohexenyl.

25 The term "alkoxy" represents an alkyl group attached through an oxygen linkage.

The term "carbonyl group" represents a carbon atom double bonded to an oxygen atom, wherein the carbon atom has two free valencies.

The term "alkoxycarbonyl" represents an alkoxy group bonded from its oxygen atom to the carbon of a carbonyl group, the carbonyl group itself being bonded to another atom through its carbon atom.

5 The term "aminocarbonyl" represents an amino group bonded from its nitrogen atom to the carbon atom of a carbonyl group, the carbonyl group itself being bonded to another atom through its carbon atom.

10 The term "lower alkyl" represents alkyl groups containing one to six carbons (C<sub>1</sub>-C<sub>6</sub>).

The term "halogen" represents fluoro, chloro, bromo, or iodo.

15 The term "aryl" refers to carbon-based rings which are aromatic. The rings may be isolated, such as phenyl, or fused, such as naphthyl. The ring hydrogens may be substituted with other groups, such as lower alkyl, or halogen.

20 The term "heteroaryl" refers to aromatic hydrocarbon rings which contain at least one heteroatom such as O, S, or N in the ring. Heteroaryl rings may be isolated, with 5 to 6 ring atoms, or fused, with 8 to 10 atoms. The heteroaryl ring(s) hydrogens or heteroatoms with open valency may be substituted with other groups, such as lower alkyl or halogen. Examples of heteroaryl groups include imidazole, pyridine, indole, quinoline, furan, thiophene, pyrrole, tetrahydroquinoline, dihydrobenzofuran, and dihydrobenzindole.

25 The compounds of this invention may be administered by any of several routes, including: a) topical ocular, intraocular injection, or irrigating solution delivery; b) application from a surgical sponge; or c) incorporation into an implantable film, viscoelastic, or other bioerodible device, which is left in the eye for sustained delivery to the affected area.

30

Generally, topical ophthalmic compositions are preferred for preventing or retarding fistula closure, and will be in the form of a solution, suspension, gel, or formulated as part of a device, such as a collagen shield or other bioerodible or non-bioerodible device. Various excipients may be contained in the topical ophthalmic solutions, suspensions or gels of the present invention. For example, buffers (e.g., borate, carbonate, phosphate), tonicity agents (e.g., sodium chloride, potassium chloride, polyols), preservatives (e.g., polyquaterniums, polybiguanides, BAC), chelating agents (e.g., EDTA), viscosity enhancing agents (e.g., polyethoxylated glycols) and solubilizing agents (e.g., polyethoxylated castor oils, including polyoxl-35 castor oil (Cremophor EL<sup>®</sup>, BASF Corp., Parsippany, NJ); Polysorbate 20, 60 and 80; Pluronic<sup>®</sup> F-68, F-84 and P-103 (BASF Corp.); or cyclodextrin) may be included in the topical ophthalmic compositions. A variety of viscoelastics and gels may be useful in topical ophthalmic gel compositions of the present invention, including, but not limited to, mucopolysaccharides (e.g. hyaluronates and chondroitin sulfates) carbomers, polyvinyl alcohol-borate complexes, or xanthan, gellan, or guar gums.

Non-solid vehicles useful for delivery of the compounds of the present invention are preferably aqueous and are formulated so as to be chemically and physically compatible with ophthalmic tissues. For example, viscoelastic formulations currently utilized in connection with intraocular surgical procedures, such as HEALON<sup>®</sup> (sodium hyaluronate) (Pharmacia Corp., Peapack, New Jersey, USA), PROVISC<sup>®</sup> (sodium hyaluronate) (Alcon Laboratories, Inc., Fort Worth, Texas, USA), or VISCOAT<sup>®</sup> (sodium chondroitin sulfate-sodium hyaluronate) (Alcon Laboratories, Inc.), or CELLUGEL<sup>®</sup> (hydroxy-propylmethyl-cellulose) are preferred as vehicles for the above-described compounds, especially for the prevention or retardation of secondary cataracts. Such viscous formulations tend to adhere to tissue.

Preferred among such viscous formulations for use in preventing or retarding secondary cataract formation are those containing hyaluronic acid or its ophthalmically acceptable salts, esters and amides, which are relatively more dispersive, i.e. less cohesive, than HEALON<sup>®</sup>, such as VISCOAT<sup>®</sup> or the hyaluronic acid amide derivatives

disclosed in WO 00/01733, the contents of which are by this reference incorporated herein. Most preferred among the viscoelastic vehicles are "non-aspirating" viscoelastics that may be left in the eye at the close of surgery without significant risk of a deleterious, post-operative intraocular pressure spike. Examples of such non-aspirating viscoelastics, including hydrophobically modified hyaluronate and especially hyaluronic acid (HA) amides, are disclosed in commonly assigned U.S. Patent Application Serial Nos. 10/111,524 and 10/111,520 the contents of which are by this reference incorporated herein. These properties help to ensure that the compositions will expose lens epithelial cells to the actions of the epothilones of the present invention. This is particularly true when the compositions are applied following removal of the natural crystallin lens, since at that point the capsular bag will be at least partially open and therefore prone to immediately losing any fluid which is applied to the interior of the bag by means of irrigation. The use of a viscous solution or semi-solid composition may therefore be preferable in some cases. In other cases, such as those where the epothilone composition is injected into the capsular bag prior to removal of the natural crystallin lens, the viscosity of the composition will not be a primary concern, since leakage of the composition from the capsular bag will be a less significant problem. The use of a less viscous aqueous solution as the vehicle may therefore be preferred in such cases.

The above-described compositions can be applied to the lens capsule by means of various techniques. For example, the compositions can be applied to the interior of the capsular bag by means of a syringe following removal of the crystallin lens, or can be injected into the lens capsule prior to removal of the crystallin lens by means of phacoemulsification or other methods.

The less viscous aqueous solutions useful as a vehicle for the compounds of the present invention, whether to reduce secondary cataract formation or fistula closure, must similarly be compatible with intraocular tissues, and should preferably help to maintain the integrity and function of intraocular tissues during or after the surgical procedure. The most basic irrigating solutions generally comprise saline, or phosphate-buffered saline. More advanced irrigating solutions, however, are preferred. As used herein, the

term "physiologically balanced irrigating solution" refers to a solution which is adapted to maintain the physical structure and function of tissues during invasive or noninvasive medical procedures. This type of solution will typically contain electrolytes, such as sodium, potassium, calcium, magnesium and/or chloride; an energy source, such as dextrose; and a bicarbonate-buffer to maintain the pH of the solution at or near physiological levels. Various solutions of this type are known (e.g., Lactated Ringers Solution), BSS® Sterile Irrigating Solution, and BSS Plus® Sterile Intraocular Irrigating Solution (Alcon Laboratories, Inc., Fort Worth, Texas, USA) are examples of physiologically balanced intraocular irrigating solutions. The latter type of solution is described in United States Patent No. 4,550,022 (Garabedian, et al.), the entire contents of which are incorporated herein by reference. Preferred aqueous solutions include physiologically balanced irrigating solutions, such as BSS® (Balanced Salt Solution) and BSS Plus® (Balanced Salt Solution Enriched with Bicarbonate, Dextrose and Glutathione) available from Alcon Laboratories, Inc., Fort Worth, Texas. Also preferred is BION TEARS® Lubricant Eye Drops, also available from Alcon Laboratories, Inc., Fort Worth, Texas.

As will be appreciated by those skilled in the art, the above-described compositions must be sterile and should not include any agents (e.g., antimicrobial preservatives) which will be toxic to sensitive ocular tissues. Preservatives can be used to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% weight/volume ("w/v"). The above-described compositions can be formulated in accordance with techniques known to those skilled in the art.

The epothilones of the invention can also be incorporated in an intraocular drug delivery system providing a slower release effect than would ordinarily be achieved with the previously discussed aqueous and viscoelastic vehicles. Topical ophthalmic bioerodible and non-bioerodible devices (e.g., conjunctival implant) are known in the art

and may be useful in the topical administration of formula (I) compounds. *See, for example*, Weiner, A.L., *Polymeric Drug Delivery Systems For The Eye*, in Polymeric Site-specific Pharmacotherapy, Ed., A.J. Domb, John Wiley & Sons, pages 316-327 (1994). While the particular ingredients and amounts to be contained in topical  
5 ophthalmic compositions useful in the methods of the present invention will vary, particular topical ophthalmic compositions will be formulated to effect the administration of a compound of formula (I) topically to the eye. The active substance in solid form could be coated with or encapsulated by an ophthalmologically acceptable carrier substance. Examples of systems, which are generally known for encapsulating drugs, are  
10 liposomes which are membrane-like vesicles, and microspheres based on polymers of lactic and glycolic acid. A slow release system can alternatively be prepared by adding the epothilone of interest in dissolved form to a carrier matrix under conditions so that a desired amount of the substance is incorporated. An example of such a carrier matrix is a gel, for instance a biodegradable gel of hyaluronic acid as disclosed in EP 408731.  
15 Additionally, a slow release composition comprising the epothilone of interest can be deposited directly on the tissue at the surgical site, under conditions so that the composition is bound to the tissue or forms an interpenetrating network with the tissue surface layer.

20 A preferred embodiment of the invention comprises intraocular administration of the epothilone compound in an amount of about 0.005 to 5  $\mu\text{g}$  and especially 0.1 to 5  $\mu\text{g}$ , in approximately 0.1 mL of a viscoelastic medium, especially PROVISC<sup>®</sup>, Healon<sup>®</sup> or Viscoat<sup>®</sup> sterile ophthalmic viscoelastic solutions. In slow release systems, the dose would preferably be considerably higher, for instance up to about 25  $\mu\text{g}$ , concentration  
25 being dictated by the volume of the vehicle or implant. Another preferred embodiment comprises irrigating solution delivery of the epothilone compound at a concentration of about 0.05 to about 100  $\mu\text{g}$  per mL.

Representative preferred formulations are described in the following Examples.



## EXAMPLE 1

Ingredient	% w/v
Compound of formula I	0.000023
Cremophor EL	0.05
Hyaluronic Acid, Sodium Salt	1
Dibasic Sodium Phosphate (Anhydrous)	0.056
Monobasic Sodium Phosphate (Monohydrate)	0.004
Sodium Chloride	0.84
Hydrochloric Acid	pH adjusted
Sodium Hydroxide	pH adjusted
Water	QS


## EXAMPLE 2

Ingredient	% w/v
Compound 1	0.00001-0.0010
Cremophor EL	0.05
Sodium Chondroitin Sulfate	4.0
Sodium Hyaluronate	3.0
Sodium Dihydrogen Phosphate, Monohydrate	0.045
Disodium Hydrogen Phosphate, Anhydrous	0.2
Sodium Chloride	0.310
Water	QS
Hydrochloric Acid	pH adjusted
Sodium Hydroxide	pH adjusted

The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

**WHAT IS CLAIMED IS:**

1. A method of reducing the formation of scar tissue or posterior capsular opacification in an eye following surgery thereon, comprising administering to the affected eye an ophthalmic composition containing a therapeutically effective amount of one or more epothilones of formula I:



wherein:

Y = O NH, or a functionally modified amino group;

OR<sup>2</sup> and OR<sup>3</sup> = same or different = a free or functionally modified hydroxy group;

Z = O, NOH, or NNH<sub>2</sub>, where the OH and NH<sub>2</sub> may be free or functionally modified;

R<sup>1</sup> = H or optionally substituted alkyl;

--- = a single or double bond;

X is a direct bond (olefin stereochemistry in this case can be *E* or *Z*), O, CH<sub>2</sub>, OCH<sub>2</sub>, CH<sub>2</sub>O, S, NH, or a functionally modified amino group;

A is *E*- or *Z*-CR<sup>5</sup>=CHR<sup>6</sup>;

R<sup>5</sup> is H, alkyl, or halogen; and

R<sup>6</sup> is is aryl, heteroaryl, cycloalkyl, cycloalkenyl, or heterocycloalkyl.

2. The method of claim 1, wherein for the compound(s) of formula I:

Y is O or NH;

5  $R^2$  and  $R^3$  are H;

Z is O;

$R^1$  is H or  $CH_3$ ;

10  $\text{---}$  = a single or double bond

X is a direct bond,  $CH_2$ , O, or NH;


15 A is *E*- or *Z*- $CR^5=CHR^6$  in the  $\beta$  position;

$R^5$  is H,  $C_{1-5}$  alkyl, or Cl; and

$R^6$  is aryl or heteroaryl.

20

3. The method of claim 2, wherein the compound(s) of formula I is(are) selected from the group consisting of:



25

4. The method according to any of claims 1-3, wherein the composition is administered during or after cataract surgery.

5. The method according to any of claims 1-3, wherein the ophthalmic composition is administered during or after glaucoma filtration surgery.

6. The method of claim 5, wherein the composition is administered to reduce the formation of scar tissue in a filtration bleb or drainage fistula of the eye.

7. A method according to claim 5, wherein the composition is administered to the surgical site *via* topical application of a pre-soaked sponge containing the composition.

15

8. A method according to any of claims 1-5, wherein the composition is administered to the eye in a surgical irrigating solution.

20

9. A method according to any of claims 1-5, wherein the composition is administered in an ophthalmically acceptable viscoelastic medium.

10. A method according to claim 9, wherein the viscoelastic medium comprises an aqueous solution of hyaluronic acid.

25

11. A method as defined by according to any of claims 1-5, wherein the compound(s) of formula I are administered using a slow release composition.

30

## INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 02/30315

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P41/00 A61P27/06 A61P27/12 A61P35/00 A61K31/427

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, MEDLINE, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 994 341 A (ARSENAULT A LARRY ET AL) 30 November 1999 (1999-11-30) column 3, line 42 -column 4, line 6 column 31, line 34 -column 35, line 62 column 36, line 23 -column 37, line 2 example 27	1-11
Y	WO 94 25020 A (MAANSSON PER ;PHARMACIA AB (SE); ROLFSEN WENCHE (SE); WICKSTROEM K) 10 November 1994 (1994-11-10) page 1, last paragraph -page 2, paragraph 5 page 3, line 8 - line 24 page 4, paragraph 2 -page 5, paragraph 2 claim 1	1-11
	---	
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

3 February 2003

Date of mailing of the international search report

27/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Langer, O

## INTERNATIONAL SEARCH REPORT

Internatl Application No

PCT/US 02/30315

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>JAMPEL HENRY D ET AL: "Glaucoma filtration surgery in nonhuman primates using taxol an etoposide in polyanhydride carriers."            INVESTIGATIVE OPHTHALMOLOGY &amp; VISUAL SCIENCE,            vol. 34, no. 11, 1993, pages 3076-3083,            XP008013191            ISSN: 0146-0404            abstract            page 3076, left-hand column, line 1 - line 5            page 3976, right-hand column, line 6-15            page 3081, left-hand column, paragraph 2            -right-hand column, paragraph 1            page 3081, right-hand column, paragraph 3            page 3082, left-hand column, paragraph 4            -right-hand column, paragraph 1</p>	1-11
Y	<p>LEGLER U F C ET AL: "INHIBITION OF POSTERIOR CAPSULE OPACIFICATION: THE EFFECT OF COLCHICINE IN A SUSTAINED DRUG DELIVERY SYSTEM"            JOURNAL CATARACT AND REFRACTIVE SURGERY, AMERICAN SOCIETY OF CATARACT AND REFRACTIVE, US,            vol. 19, no. 4, 1 July 1993 (1993-07-01),            pages 462-470, XP000565374            ISSN: 0886-3350            abstract            page 462, right-hand column, paragraph 2            -page 463, left-hand column, paragraph 1            page 464, left-hand column, last paragraph            -right-hand column, paragraph 2            page 466, right-hand column, paragraph 2            page 467, left-hand column, paragraph 3            page 467, left-hand column, paragraph 5            -right-hand column, paragraph 1</p>	1-11
Y	<p>WELLER M ET AL: "EVALUATION OF DAUNOMYCIN TOXICITY ON LENS EPITHELIUM IN-VITRO"            INTERNATIONAL OPHTHALMOLOGY,            vol. 12, no. 2, 1988, pages 127-130,            XP008013199            ISSN: 0165-5701            page 128, right-hand column, paragraph 3            page 129, left-hand column, paragraph 2            page 130, left-hand column, paragraph 4 - paragraph 10</p>	1-11

-/--

## INTERNATIONAL SEARCH REPORT

 Internat Application No  
 PCT/US 02/30315

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	COSTA V P ET AL: "WOUND HEALING MODULATION IN GLAUCOMA FILTRATION SURGERY" OPHTHALMIC SURGERY, SLACK, PITMAN, NJ, US, vol. 24, no. 3, March 1993 (1993-03), pages 152-170, XP002923717 ISSN: 0022-023X page 156, left-hand column, paragraph 2 -right-hand column, paragraph 7 page 157, right-hand column, paragraph 4 -page 158, left-hand column, paragraph 1 page 158, right-hand column, paragraph 3 ---	1-11
Y	MEMBREY W L ET AL: "Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 1 Intraocular pressure control and complications." BRITISH JOURNAL OF OPHTHALMOLOGY, vol. 84, no. 6, June 2000 (2000-06), pages 586-590, XP002229604 ISSN: 0007-1161 abstract ---	1-11
Y	LEE D A ET AL: "THE USE OF BIOERODIBLE POLYMERS AND 5-FLUOROURACIL IN GLAUCOMA FILTRATION SURGERY" INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 29, no. 11, 1 November 1988 (1988-11-01), pages 1692-1697, XP000565392 ISSN: 0146-0404 abstract page 1696, right-hand column, paragraph 3 ---	1-11
Y	TURACLI E ET AL: "A COMPARATIVE CLINICAL TRIAL OF MITOMYCIN C AND CYCLOSPORIN A IN TRABECULECTOMY" EUROPEAN JOURNAL OF OPHTHALMOLOGY, MILAN, IT, vol. 6, no. 4, 1996, pages 398-401, XP009003662 ISSN: 1120-6721 abstract --- -/--	1-11

## INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/US 02/30315

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ISHIOKA MISAKI ET AL: "Trabeculectomy with mitomycin C for post-keratoplasty glaucoma."  BRITISH JOURNAL OF OPHTHALMOLOGY,  vol. 84, no. 7, July 2000 (2000-07), pages 714-717, XP002229605  ISSN: 0007-1161  abstract  page 714, left-hand column, paragraph 1  page 717, left-hand column, paragraph 3  page 717, right-hand column, paragraph 3  table 1  figures 1,2</p>	1-11
Y	<p>JACOBI PHILIPP C ET AL: "Adjunctive mitomycin C in primary trabeculectomy in young adults: A long-term study of case-matched young patients."  GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY,  vol. 236, no. 9, 1998, pages 652-657, XP002229606  ISSN: 0721-832X  abstract  page 652, right-hand column, paragraph 2  -page 653, left-hand column, line 2</p>	1-11
Y	<p>BOLLAG ET AL: "Epothilones a new class of microtubule-stabilizing agents with a taxol-like mechanism of action"  CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US,  vol. 55, 1 June 1995 (1995-06-01), pages 2325-2333, XP002111282  ISSN: 0008-5472  abstract  page 2327, right-hand column, paragraph 6  -page 2328, left-hand column, paragraph 2  page 2328, right-hand column, paragraph 2  -page 2329, right-hand column, line 2  page 2332, left-hand column, paragraph 3  -right-hand column, paragraph 4</p>	1-11
Y	<p>CHOU T C ET AL: "DESOXYEPOTHILONE B: AN EFFICACIOUS MICROTUBULE-TARGETED ANTITUMOR AGENT WITH A PROMISING IN VIVO PROFILE RELATIVE TO EPOTHILONE B"  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US,  vol. 95, no. 16, 1998, pages 9642-9647, XP000910107  ISSN: 0027-8424  abstract  page 9642, right-hand column, paragraph 2</p>	1-11

-/--



## INTERNATIONAL SEARCH REPORT

Internati      Application No  
PCT/US 02/30315

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99 54318 A (SQUIBB BRISTOL MYERS CO) 28 October 1999 (1999-10-28) cited in the application formulae I and II on page 1 page 7, line 26 -page 9, line 6 ---	1-11
Y	WO 99 67252 A (NOVARTIS ERFINDE VERWALT GMBH ;NOVARTIS AG (CH); VALLBERG HANS (SE)) 29 December 1999 (1999-12-29) cited in the application page 1, paragraph 3 -page 2, paragraph 1 ---	1-11
Y	WANG M ET AL: "A UNIFIED AND QUANTITATIVE RECEPTOR MODEL FOR THE MICROTUBULE BINDING OF PACLITAXEL AND EPOTHILONE" ORGANIC LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 1, no. 1, January 1999 (1999-01), pages 43-46, XP000983329 ISSN: 1523-7060 page 43, left-hand column, line 5 - line 7 page 43, right-hand column, line 6 -page 44, left-hand column, line 7 page 46, left-hand column, paragraph 2 ---	1-11
Y	WO 00 49021 A (KLAR ULRICH ;SCHERING AG (DE); BUCHMANN BERND (DE); SKUBALLA WERNE) 24 August 2000 (2000-08-24) cited in the application abstract page 2, line 26 - line 30 page 10 -page 17 ---	1-11
Y	WO 99 43653 A (SLOAN KETTERING INST CANCER) 2 September 1999 (1999-09-02) cited in the application page 1, line 30 - line 33 page 2, line 3 - line 9 page 12, line 4 - line 8 ---	1-11
A	ALTMANN K-H ET AL: "Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity" BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1470, no. 3, 17 May 2000 (2000-05-17), pages M79-M91, XP004281887 ISSN: 0304-419X the whole document --- -/--	1-11

## INTERNATIONAL SEARCH REPORT

Internatl Application No

PCT/US 02/30315

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>APPLE D J ET AL: "POSTERIOR CAPSULE OPACIFICATION" SURVEY OF OPHTHALMOLOGY, SURVEY OF OPHTHALMOLOGY INC, XX, vol. 37, no. 2, September 1992 (1992-09), pages 73-116, XP001098853 ISSN: 0039-6257 abstract page 104, left-hand column, last paragraph -page 105, left-hand column, paragraph 2 -----</p>	1-11

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The expressions 'optionally substituted alkyl', 'functionally modified hydroxy group', and 'functionally modified amino group' in claim 1 are considered to be unclear under Article 6 PCT. The search has been restricted for R1 to unsubstituted alkyl and alkyl substituted according to the definition on page 9, last paragraph and for X, Y, and Z to the unsubstituted ("free") functional groups and the modifications as defined on page 8, last paragraph to page 9, first paragraph.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 02/30315

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatic Application No

PCT/US 02/30315

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5994341	A	30-11-1999	US 2003004209 A1 02-01-2003
			AU 693797 B2 09-07-1998
			AU 7119294 A 20-02-1995
			DE 69403966 D1 31-07-1997
			DE 69403966 T2 05-02-1998
			EP 0706376 A1 17-04-1996
			GR 3024833 T3 30-01-1998
			JP 9503488 T 08-04-1997
			NO 960226 A 18-03-1996
			NZ 268326 A 19-12-1997
			US 2002164377 A1 07-11-2002
			US 5886026 A 23-03-1999
			US 5716981 A 10-02-1998
			US 2003003094 A1 02-01-2003
			US 2002119202 A1 29-08-2002
			US 2002165265 A1 07-11-2002
			AT 154757 T 15-07-1997
			AU 6991198 A 16-07-1998
			CA 2167268 A1 02-02-1995
			WO 9503036 A1 02-02-1995
			CN 1130866 A 11-09-1996
			DK 706376 T3 13-10-1997
			EP 1155689 A2 21-11-2001
			EP 1155690 A2 21-11-2001
			EP 1159974 A1 05-12-2001
			EP 1155691 A2 21-11-2001
			EP 1159975 A2 05-12-2001
			EP 0797988 A2 01-10-1997
			ES 2106553 T3 01-11-1997
			JP 2002326930 A 15-11-2002
			NZ 329193 A 31-08-2001
			RU 2180844 C2 27-03-2002
WO 9425020	A	10-11-1994	AT 188872 T 15-02-2000
			AU 6694194 A 21-11-1994
			CA 2161697 A1 10-11-1994
			DE 69422707 D1 24-02-2000
			DE 69422707 T2 03-08-2000
			DK 696917 T3 26-06-2000
			EP 0696917 A1 21-02-1996
			ES 2143546 T3 16-05-2000
			GR 3033149 T3 31-08-2000
			JP 8509494 T 08-10-1996
			PT 696917 T 30-06-2000
			WO 9425020 A1 10-11-1994
			US 5576345 A 19-11-1996
WO 9954318	A	28-10-1999	AU 3382799 A 08-11-1999
			AU 748526 B2 06-06-2002
			AU 3471699 A 08-11-1999
			BR 9909795 A 26-12-2000
			CA 2323609 A1 28-10-1999
			CA 2329181 A1 28-10-1999
			CN 1298398 T 06-06-2001
			EP 1073647 A1 07-02-2001
			EP 1073648 A1 07-02-2001
			JP 2002512238 T 23-04-2002
			JP 2002512239 T 23-04-2002

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/30315

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9954318 A		TR 200003036 T2	22-01-2001
		WO 9954318 A1	28-10-1999
		WO 9954319 A1	28-10-1999
		US 6399638 B1	04-06-2002
		US 6380395 B1	30-04-2002
WO 9967252 A	29-12-1999	US 6380394 B1	30-04-2002
		AU 4774899 A	10-01-2000
		AU 4775299 A	10-01-2000
		BR 9911420 A	20-03-2001
		CA 2334342 A1	29-12-1999
		CN 1306531 T	01-08-2001
		WO 9967252 A2	29-12-1999
		WO 9967253 A2	29-12-1999
		EP 1089998 A2	11-04-2001
		HU 0102711 A2	28-12-2001
		JP 2002518504 T	25-06-2002
		NO 20006378 A	21-02-2001
		PL 345327 A1	17-12-2001
		SK 19712000 A3	11-09-2001
		TR 200003844 T2	20-04-2001
WO 0049021 A	24-08-2000	DE 19908765 A1	24-08-2000
		DE 19954230 A1	15-11-2001
		AU 3156700 A	04-09-2000
		BG 105802 A	29-03-2002
		BR 0008331 A	29-01-2002
		CA 2361278 A1	24-08-2000
		CN 1341115 T	20-03-2002
		CZ 20012951 A3	14-11-2001
		EE 200100431 A	16-12-2002
		WO 0049021 A2	24-08-2000
		EP 1150980 A2	07-11-2001
		HU 0105478 A2	29-06-2002
		JP 2002537301 T	05-11-2002
		NO 20014013 A	18-10-2001
		PL 349863 A1	23-09-2002
		SK 11852001 A3	04-04-2002
WO 9943653 A	02-09-1999	AU 2785899 A	15-09-1999
		CA 2322157 A1	02-09-1999
		EP 1058679 A1	13-12-2000
		JP 2002504540 T	12-02-2002
		WO 9943653 A1	02-09-1999
		US 6204388 B1	20-03-2001
		US 6316630 B1	13-11-2001
		ZA 9901497 A	24-08-1999